A Comparison of Cyclophosphamide, Bortezomib, and Dexamethasone Versus Bortezomib and Dexamethasone in Transplant Eligible Patients with Newly Diagnosed Multiple Myeloma

被引：0
|
作者：
Figueiredo, Amarilis [1 ]
Atkins, Harold [1 ,2 ,3 ,4 ]
Mallick, Ranjeeta [5 ,6 ]
Kekre, Natasha [1 ,2 ,3 ,4 ]
Kew, Andrea [2 ,3 ,4 ]
McCurdy, Arleigh [1 ,3 ,4 ]
机构：
[1] Ottawa Hosp Res Inst, Ottawa, ON, Canada
[2] Ottawa Hosp, Div Hematol, Ottawa, ON, Canada
[3] Ottawa Hosp, Dept Med, Ottawa, ON, Canada
[4] Univ Ottawa, Ottawa, ON, Canada
[5] Univ Ottawa, Sch Epidemiol, Publ Hlth & Prevent Med, Ottawa, ON, Canada
[6] Ottawa Hosp Res Inst, Clin Epidemiol Program, Ottawa, ON, Canada
来源：
BLOOD | 2016年 / 128卷 / 22期
关键词：
D O I：
10.1182/blood.V128.22.4519.4519
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
4519
引用
收藏
页数：5
相关论文
共 50 条
  • [21] Bortezomib-cyclophosphamide-dexamethasone induction/consolidation and bortezomib maintenance for transplant-eligible newly diagnosed multiple myeloma: phase 2 multicenter trial
    Muranushi, Hiroyuki
    Kanda, Junya
    Kobayashi, Masayuki
    Maeda, Takeshi
    Kitano, Toshiyuki
    Tsuji, Masaaki
    Ueda, Yasunori
    Ishikawa, Takayuki
    Nohgawa, Masaharu
    Watanabe, Mitsumasa
    Imada, Kazunori
    Moriguchi, Toshinori
    Itoh, Mitsuru
    Ohno, Hitoshi
    Yonezawa, Akihito
    Hirata, Hirokazu
    Arima, Nobuyoshi
    Asagoe, Kohsuke
    Anzai, Naoyuki
    Nagata, Kayoko
    Yasuno, Shinji
    Kuwabara, Yoshihiro
    Kitao, Hiromi
    Kim, Ihhwa
    Kawagishi, Kiyomi
    Ueshima, Kenji
    Tominari, Shinjiro
    Nakayama, Takeo
    Yamashita, Kouhei
    Takaori-Kondo, Akifumi
    HEMATOLOGY, 2022, 27 (01) : 239 - 248
  • [22] Daratumumab, lenalidomide, bortezomib, and dexamethasone for transplant-eligible newly diagnosed multiple myeloma: the GRIFFIN trial
    Voorhees, Peter M.
    Kaufman, Jonathan L.
    Laubach, Jacob
    Sborov, Douglas W.
    Reeves, Brandi
    Rodriguez, Cesar
    Chari, Ajai
    Silbermann, Rebecca
    Costa, Luciano J.
    Anderson, Larry D., Jr.
    Nathwani, Nitya
    Shah, Nina
    Efebera, Yvonne A.
    Holstein, Sarah A.
    Costello, Caitlin
    Jakubowiak, Andrzej
    Wildes, Tanya M.
    Orlowski, Robert Z.
    Shain, Kenneth H.
    Cowan, Andrew J.
    Murphy, Sean
    Lutska, Yana
    Pei, Huiling
    Ukropec, Jon
    Vermeulen, Jessica
    de Boer, Carla
    Hoehn, Daniela
    Lin, Thomas S.
    Richardson, Paul G.
    BLOOD, 2020, 136 (08) : 936 - 945
  • [23] Integrated Analysis of Bortezomib-Lenalidomide-Dexamethasone vs Bortezomib-Thalidomide-Dexamethasone in Transplant-Eligible Newly Diagnosed Myeloma
    Rosinol, Laura
    Hebraud, Benjamin
    Oriol, Albert
    Colin, Anne-Laurene
    Tamayo, Rafael Rios
    Hulin, Cyrille
    Blanchard, Maria Jesus
    Caillot, Denis
    Balari, Anna Sureda
    Hernandez, Miguel T.
    Arnulf, Bertrand
    Mateos, Maria-Victoria
    Macro, Margaret
    San-Miguel, Jesus
    Belhadj, Karim
    Lahuerta, Juan-Jose
    Garelik, M. Brigid
    Blade, Joan
    Moreau, Philippe
    Attal, Michel
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2019, 19 (10): : E1 - E2
  • [24] Bortezomib, Thalidomide and Dexamethasone Compared to Cyclophosphamide, Bortezomib and Dexamethasone As Induction Therapy for the Treatment of Transplant Eligible Multiple Myeloma: Real World Experience with Multiple Myeloma Patients in Colombia
    Cesar Solano, Julio
    BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 2020, 26 (03) : S248 - S248
  • [25] Canadian Retrospective Multicentric Study Comparing the Combination of Bortezomib, Cyclophosphamide and Dexamethasone (Cybord) Versus Bortezomib, Thalidomide and Dexamethasone (VTD) Versus Bortezomib and Dexamethasone (Vd) in Patients with Newly Diagnosed Multiple Myeloma Eligible for Autologous Hematopoietic Stem Cell Transplantation (HCT)
    Yamga, Eric
    Leblanc, Richard
    Boudreault, Jean-Samuel
    BLOOD, 2018, 132
  • [26] Bortezomib, cyclophosphamide, dexamethasone versus lenalidomide, cyclophosphamide, dexamethasone in multiple myeloma patients at first relapse
    Montefusco, Vittorio
    Corso, Alessandro
    Galli, Monica
    Ardoino, Ilaria
    Pezzatti, Sara
    Carniti, Cristina
    Patriarca, Francesca
    Gherlinzoni, Filippo
    Zambello, Renato
    Sammassimo, Simona
    Marcatti, Magda
    Nozza, Andrea
    Crippa, Claudia
    Cafro, Anna Maria
    Baldini, Luca
    Corradini, Paolo
    BRITISH JOURNAL OF HAEMATOLOGY, 2020, 188 (06) : 907 - 917
  • [27] Daratumumab plus lenalidomide/bortezomib/dexamethasone in Black patients with transplant-eligible newly diagnosed multiple myeloma in GRIFFIN
    Nooka, Ajay K.
    Kaufman, Jonathan L.
    Rodriguez, Cesar
    Jakubowiak, Andrzej
    Efebera, Yvonne
    Reeves, Brandi
    Wildes, Tanya
    Holstein, Sarah A.
    Anderson, Larry D., Jr.
    Badros, Ashraf
    Shune, Leyla
    Chari, Ajai
    Pei, Huiling
    Cortoos, Annelore
    Patel, Sharmila
    Bartlett, J. Blake
    Vermeulen, Jessica
    Lin, Thomas S.
    Richardson, Paul G.
    Voorhees, Peter
    BLOOD CANCER JOURNAL, 2022, 12 (04)
  • [28] The efficacy and safety of modified bortezomib-lenalidomide-dexamethasone in transplant-eligible patients with newly diagnosed multiple myeloma
    Okazuka, Kiyoshi
    Ishida, Tadao
    Nashimoto, Junichiro
    Uto, Yui
    Sato, Kota
    Miyazaki, Kanji
    Ogura, Mizuki
    Yoshiki, Yumiko
    Abe, Yu
    Tsukada, Nobuhiro
    Suzuki, Kenshi
    EUROPEAN JOURNAL OF HAEMATOLOGY, 2020, 104 (02) : 110 - 115
  • [29] Bortezomib, lenalidomide, and dexamethasone in transplant-eligible newly diagnosed multiple myeloma patients: a multicenter retrospective comparative analysis
    Suzuki, Kazuhito
    Tsukada, Nobuhiro
    Nishimura, Noriko
    Nagata, Yasuyuki
    Okazuka, Kiyoshi
    Mishima, Yuko
    Yokoyama, Masahiro
    Nishiwaki, Kaichi
    Ishida, Tadao
    Yano, Shingo
    Terui, Yasuhito
    Suzuki, Kenshi
    INTERNATIONAL JOURNAL OF HEMATOLOGY, 2020, 111 (01) : 103 - 111
  • [30] Daratumumab plus lenalidomide/bortezomib/dexamethasone in Black patients with transplant-eligible newly diagnosed multiple myeloma in GRIFFIN
    Ajay K. Nooka
    Jonathan L. Kaufman
    Cesar Rodriguez
    Andrzej Jakubowiak
    Yvonne Efebera
    Brandi Reeves
    Tanya Wildes
    Sarah A. Holstein
    Larry D. Anderson
    Ashraf Badros
    Leyla Shune
    Ajai Chari
    Huiling Pei
    Annelore Cortoos
    Sharmila Patel
    J. Blake Bartlett
    Jessica Vermeulen
    Thomas S. Lin
    Paul G. Richardson
    Peter Voorhees
    Blood Cancer Journal, 12
12345